Cross-Sex Hormones

The Origins and Evolution of a Clinical Ideal Growth happens one intentional step at a time, but when those steps are taken without a firm foundation of evidence, the path can lead toward systemic crisis. The Gender Identity Development Service (GIDS) began in 1989 as the brainchild of Domenico de Ceglie. At its inception, it was a small, specialist service designed to support young people experiencing deep distress regarding a mismatch between their biological sex and their gender identity. In those early years, the clinic operated on a model of psychological exploration. The goal was simple: provide a safe harbor where children could understand their feelings through talking therapies, managing uncertainty without the immediate pressure of medical intervention. By the mid-1990s, the service moved to the Tavistock and Portman NHS Foundation Trust. For over a decade, it remained a cautious environment. Puberty blockers were available, but only for those sixteen and older—those who had already navigated the biological milestone of puberty. This was a slow, contemplative approach that recognized the fluidity of adolescence. It understood that a child’s strength of feeling, however intense, might not always indicate a permanent identity. However, as the 2000s progressed, the clinic faced growing pressure to lower the age of intervention, influenced by a pioneering Dutch team that had begun medicating younger cohorts. The Shift from Exploration to Medicalization In 2011, the clinic initiated a research study involving forty-four young people as young as twelve. The intention was to gather data on the effects of early intervention. Strikingly, GIDS did not wait for the results of this study before fundamentally altering its policy. By 2014, the service moved from an age-based approach to a stage-based approach, allowing children at the very onset of puberty—sometimes as young as nine or ten—to begin chemical blockers. This was a pivotal moment where the clinic transitioned from a therapeutic project into what leadership later described as a "justice project." This shift coincided with a demographic explosion. Between 2009 and 2016, referrals skyrocketed from under a hundred per year to over fourteen hundred. More significantly, the patient profile flipped. Previously, the majority of patients were biological males with lifelong gender incongruence. Suddenly, the clinic saw a massive influx of biological females whose distress began after the onset of puberty. These young people often presented with complex, co-occurring difficulties: eating disorders, depression, history of trauma, and autism. Despite the lack of a robust evidence base for this specific new cohort, the medical pathway became the primary, and often only, treatment offered. The Myth of the Reversible Pause The central justification for early intervention was the idea that Puberty Blockers provide "time and space" to think. The theory suggests that by pausing the physical changes of puberty, a child’s distress is alleviated, allowing them to make a more informed decision about their future. However, investigative journalist Hannah Barnes found that the reality within the clinic often contradicted this theory. Once a child was placed on blockers, the frequency of their psychological appointments often decreased rather than increased. Instead of creating space for exploration, the blockers appeared to act as a "one-way street." Data eventually revealed that nearly every young person who started the blocker proceeded to cross-sex hormones. This high persistence rate challenged the narrative of reversibility. If the blocker were truly a neutral pause, we would expect to see a variety of outcomes. Furthermore, the long-term impact on bone density, brain development, and future fertility remains poorly understood. When the clinic’s own data in 2015 and 2016 showed no measurable psychological improvement in children on blockers—and in some cases, a decline in mental health—the practice continued unabated. This highlights a dangerous disconnect between clinical results and institutional policy. Systemic Failure and the Burden of Responsibility The collapse of GIDS is not the result of a single villain but a profound systemic failure across multiple layers of oversight. The leadership at the Tavistock Trust failed to take internal safeguarding concerns seriously, even when brought forward by a sizable number of concerned staff. NHS England provided inadequate oversight, allowing the rollout of early-intervention policies without requiring robust, long-term data collection. Even the Care Quality Commission did not inspect the service for several years during its period of most rapid growth. There was also a significant external influence from advocacy groups like Mermaids. While these organizations were not running the clinic, their presence was felt in every consultation room. Clinicians reported a fear of backlash if they questioned the medical model or suggested that a child’s distress might be rooted in something other than gender, such as neurodiversity or trauma. This environment discouraged the "differential diagnosis" that is standard in every other branch of medicine. When ideology trumps evidence, the most vulnerable people—the children—are the ones who pay the price. Reclaiming a Holistic Path to Resilience True growth involves looking at the whole person, not just a single symptom. The investigation into GIDS reveals that many referred children were struggling with deep-seated trauma or were simply gay and navigating the confusion of same-sex attraction in a highly sexualized world. By framing every instance of adolescent distress through the lens of gender identity, the clinic may have overlooked the underlying needs of its patients. Resilience is built when we help young people navigate their challenges with clarity and self-awareness, rather than rushing toward irreversible medical solutions. The future of gender care in the UK is shifting toward a more regionalized, holistic model. The new services signaled by the Cass Review emphasize psychological support, neurodiversity expertise, and rigorous data collection as the first line of care. This move back toward a therapeutic foundation is a necessary step in restoring clinical integrity. It reminds us that our greatest power lies in the courage to ask difficult questions and the patience to wait for evidence-based answers. Navigating the complexities of the human identity requires an empathetic, slow, and deeply intentional approach.